ES2722824T3 - Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI) - Google Patents
Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI) Download PDFInfo
- Publication number
- ES2722824T3 ES2722824T3 ES12762959T ES12762959T ES2722824T3 ES 2722824 T3 ES2722824 T3 ES 2722824T3 ES 12762959 T ES12762959 T ES 12762959T ES 12762959 T ES12762959 T ES 12762959T ES 2722824 T3 ES2722824 T3 ES 2722824T3
- Authority
- ES
- Spain
- Prior art keywords
- tissue factor
- pathway inhibitor
- seq
- factor pathway
- tfpi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161471101P | 2011-04-01 | 2011-04-01 | |
| PCT/US2012/031538 WO2012135671A2 (en) | 2011-04-01 | 2012-03-30 | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2722824T3 true ES2722824T3 (es) | 2019-08-19 |
Family
ID=46932389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12762959T Active ES2722824T3 (es) | 2011-04-01 | 2012-03-30 | Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI) |
Country Status (37)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102348462B (zh) | 2008-12-19 | 2015-06-17 | 巴克斯特国际公司 | Tfpi抑制剂和使用方法 |
| BRPI0924058B1 (pt) † | 2008-12-22 | 2021-08-17 | Novo Nordisk A/S | Anticorpos monoclonais, seus usos, bem como composição farmacêutica |
| PT3345615T (pt) | 2010-03-01 | 2020-01-17 | Bayer Healthcare Llc | Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi) |
| AU2011227714B2 (en) | 2010-03-19 | 2014-09-04 | Takeda Pharmaceutical Company Limited | TFPI inhibitors and methods of use |
| KR20190079698A (ko) * | 2011-04-01 | 2019-07-05 | 바이엘 헬스케어 엘엘씨 | 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 모노클로날 항체 |
| ES2733958T3 (es) | 2012-03-21 | 2019-12-03 | Baxalta GmbH | Inhibidores de TFPI y métodos de uso |
| SG11201406129QA (en) * | 2012-03-30 | 2014-10-30 | Bayer Healthcare Llc | Protease-regulated antibodies |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| ES2657304T3 (es) | 2013-03-15 | 2018-03-02 | Bayer Healthcare Llc | Variantes de anticuerpo anti TFPI con unión diferencial a lo largo del intervalo de pH para mejorar la farmacocinética |
| ES2926773T3 (es) * | 2013-03-15 | 2022-10-28 | Novo Nordisk As | Anticuerpos capaces de unirse específicamente a dos epítopos en el inhibidor de la ruta del factor tisular |
| EP3022228B1 (en) * | 2013-07-19 | 2019-02-27 | Novo Nordisk A/S | Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity |
| ES2905085T3 (es) * | 2014-09-17 | 2022-04-07 | Novo Nordisk As | Anticuerpos que pueden unirse a dos epítopos en el inhibidor de la vía del factor tisular (1-161) |
| EP3262075B1 (en) * | 2015-02-25 | 2024-03-13 | Mogam Institute For Biomedical Research | Novel antibody binding to tfpi and composition comprising the same |
| RU2705540C2 (ru) * | 2015-08-19 | 2019-11-07 | Пфайзер Инк. | Антитела против ингибитора пути тканевого фактора и их применения |
| CN112424593A (zh) * | 2018-07-25 | 2021-02-26 | 索尼公司 | 凝血系统分析装置 |
| CN112442127A (zh) * | 2019-08-29 | 2021-03-05 | 苏州康宁杰瑞生物科技有限公司 | 针对tfpi的单克隆抗体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06153985A (ja) * | 1992-11-16 | 1994-06-03 | Teijin Ltd | モノクローナル抗体 |
| UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
| BRPI0924058B1 (pt) * | 2008-12-22 | 2021-08-17 | Novo Nordisk A/S | Anticorpos monoclonais, seus usos, bem como composição farmacêutica |
| PT3345615T (pt) * | 2010-03-01 | 2020-01-17 | Bayer Healthcare Llc | Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi) |
| KR20190079698A (ko) * | 2011-04-01 | 2019-07-05 | 바이엘 헬스케어 엘엘씨 | 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 모노클로날 항체 |
| US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| US8613919B1 (en) * | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
-
2012
- 2012-03-30 KR KR1020197018445A patent/KR20190079698A/ko not_active Ceased
- 2012-03-30 ES ES12762959T patent/ES2722824T3/es active Active
- 2012-03-30 RS RS20190338A patent/RS58633B1/sr unknown
- 2012-03-30 SG SG2013071477A patent/SG193594A1/en unknown
- 2012-03-30 EP EP12762959.0A patent/EP2694544B1/en active Active
- 2012-03-30 AU AU2012236296A patent/AU2012236296A1/en not_active Abandoned
- 2012-03-30 DK DK12762959.0T patent/DK2694544T3/en active
- 2012-03-30 MX MX2013011218A patent/MX2013011218A/es unknown
- 2012-03-30 BR BR112013025376A patent/BR112013025376A2/pt active Search and Examination
- 2012-03-30 EA EA201991704A patent/EA201991704A3/ru unknown
- 2012-03-30 CN CN201280026938.XA patent/CN103797030B/zh not_active Expired - Fee Related
- 2012-03-30 SG SG10201602606UA patent/SG10201602606UA/en unknown
- 2012-03-30 CA CA3068997A patent/CA3068997A1/en not_active Abandoned
- 2012-03-30 MY MYPI2017001205A patent/MY190951A/en unknown
- 2012-03-30 UA UAA201312686A patent/UA113623C2/uk unknown
- 2012-03-30 WO PCT/US2012/031538 patent/WO2012135671A2/en not_active Ceased
- 2012-03-30 SI SI201231558T patent/SI2694544T1/sl unknown
- 2012-03-30 LT LTEP12762959.0T patent/LT2694544T/lt unknown
- 2012-03-30 PL PL12762959T patent/PL2694544T3/pl unknown
- 2012-03-30 HU HUE12762959A patent/HUE042706T2/hu unknown
- 2012-03-30 EA EA201301107A patent/EA034214B1/ru not_active IP Right Cessation
- 2012-03-30 PT PT12762959T patent/PT2694544T/pt unknown
- 2012-03-30 TR TR2019/05101T patent/TR201905101T4/tr unknown
- 2012-03-30 US US14/009,334 patent/US20140294832A1/en not_active Abandoned
- 2012-03-30 JP JP2014502846A patent/JP6170903B2/ja not_active Expired - Fee Related
- 2012-03-30 CN CN201710275470.2A patent/CN107090046A/zh active Pending
- 2012-03-30 HR HRP20190467TT patent/HRP20190467T1/hr unknown
- 2012-03-30 PE PE2013002137A patent/PE20141149A1/es active IP Right Grant
- 2012-03-30 KR KR1020137028821A patent/KR101995302B1/ko not_active Expired - Fee Related
- 2012-03-30 MY MYPI2013701814A patent/MY165499A/en unknown
- 2012-03-30 CA CA2831907A patent/CA2831907C/en not_active Expired - Fee Related
-
2013
- 2013-09-27 GT GT201300229A patent/GT201300229A/es unknown
- 2013-09-30 CU CU2013000128A patent/CU20130128A7/es unknown
- 2013-09-30 PH PH12013502039A patent/PH12013502039B1/en unknown
- 2013-09-30 CR CR20130499A patent/CR20130499A/es unknown
- 2013-09-30 IL IL228633A patent/IL228633B/en active IP Right Grant
- 2013-09-30 CL CL2013002811A patent/CL2013002811A1/es unknown
- 2013-09-30 DO DO2013000218A patent/DOP2013000218A/es unknown
- 2013-10-01 CO CO13233113A patent/CO6890074A2/es unknown
- 2013-10-01 EC ECSP13012913 patent/ECSP13012913A/es unknown
- 2013-10-31 ZA ZA2013/08169A patent/ZA201308169B/en unknown
-
2016
- 2016-07-27 US US15/221,104 patent/US20170107298A1/en not_active Abandoned
-
2017
- 2017-02-17 JP JP2017027825A patent/JP6363747B2/ja not_active Expired - Fee Related
- 2017-05-10 AU AU2017203105A patent/AU2017203105A1/en not_active Abandoned
-
2018
- 2018-01-22 US US15/877,349 patent/US20180194857A1/en not_active Abandoned
- 2018-01-25 IL IL257145A patent/IL257145A/en unknown
- 2018-02-22 HK HK18102557.1A patent/HK1243426A1/zh unknown
- 2018-06-28 JP JP2018122610A patent/JP2018172411A/ja active Pending
- 2018-12-27 US US16/234,239 patent/US20190194353A1/en not_active Abandoned
-
2019
- 2019-02-28 PH PH12019500439A patent/PH12019500439A1/en unknown
- 2019-02-28 PH PH12019500440A patent/PH12019500440A1/en unknown
- 2019-02-28 PH PH12019500441A patent/PH12019500441A1/en unknown
- 2019-03-15 AU AU2019201814A patent/AU2019201814A1/en not_active Abandoned
- 2019-03-22 CY CY20191100343T patent/CY1121538T1/el unknown
-
2020
- 2020-05-14 IL IL274686A patent/IL274686B/en unknown
- 2020-10-20 JP JP2020176145A patent/JP2021019619A/ja not_active Withdrawn
-
2021
- 2021-03-24 US US17/211,631 patent/US20220041752A1/en not_active Abandoned
- 2021-06-09 IL IL283829A patent/IL283829A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2722824T3 (es) | Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI) | |
| PE20161032A1 (es) | Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion | |
| CU24568B1 (es) | Anticuerpo inhibidor de masp-3 | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| UY37694A (es) | Dominios de unión a antígeno humanizados y métodos de uso | |
| PE20171060A1 (es) | Receptores quimericos de antigeno anti-cldn y metodos de uso | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| CL2012000518A1 (es) | Uso de un anticuerpo aislado o fragmento de enlace antígeno del mismo que comprende una región variable de cadena ligera y una de cadena pesada (sec nº38 y nº40) útil en el tratamiento y prevención de mieloma en un mamífero (div. sol. 3615-07). | |
| AR099812A1 (es) | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr | |
| MX360707B (es) | Receptor antigénico quimérico. | |
| PE20140814A1 (es) | Anticuerpos contra la angiopoyetina 2 humana | |
| CL2016000324A1 (es) | Anticuerpos monoclonales que se unen especificamente al inhibidor del activador de plasminogeno de tipo 1 (pai-1); y uso para preparar un medicamento util para restaurar la generación de plasmina o tratar una afeccion causada por el aumento de los niveles de pai-1 o el aumento de la sensibilidad a pai-1. | |
| PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| CY1121158T1 (el) | Αντισωμα ικανο να αναγνωριζει ειδικα υποδοχεα τρανσφερρινης | |
| PE20181805A1 (es) | Composiciones y anticuerpos anti-tim-3 | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| PE20180927A1 (es) | Moleculas de union a lag-3 y metodos de uso de las mismas | |
| MY166776A (en) | Humanised anti-ctla4 antibodies | |
| AR077595A1 (es) | Tratamientos de combinacion | |
| PE20141398A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| PE20091196A1 (es) | Anticuerpos contra el vegf completamente humano, composiciones y metodos | |
| CY1116488T1 (el) | Αντισωματα anti-προπερδινης | |
| PE20120427A1 (es) | Anticuerpos contra el receptor de cgrp humano |